XLH UK
XLH UK is a patient-led UK charity supporting individuals and families affected by X-linked hypophosphataemia and related phosphate-wasting disorders through education, peer support, research participation, and NHS access advocacy.
- Company typePrivate
- Founded2021
- HeadquartersKington, United Kingdom
- Headcount1–10
- GTM typeB2C
- OfferingServices
What XLH UK does
XLH UK is a patient-led charity registered in England and Wales (Charity number 1196811), founded in 2021 and headquartered in Kington, United Kingdom. It is the only UK-dedicated organization focused on X-linked hypophosphataemia (XLH) and related phosphate-wasting disorders, serving individuals diagnosed with the condition, their families, treating clinicians, and researchers studying rare bone disease.
The charity's core offerings are delivered through a WordPress-based website (xlhuk.org) and an in-person events program rather than a traditional technology product stack. Core services include disease and treatment information (with a specific educational track on burosumab, including the pre-filled syringe rollout), an XLH Connect peer-to-peer support program, a specialist finder tool, the downloadable XLH Library of clinical recommendations and research publications, and facilitated participation in the University of Oxford-led RUDY Study, which collects patient-reported outcomes on XLH symptoms, medicines, and quality of life.
XLH UK is funded through donations, individual fundraising campaigns (including half-marathon participation on platforms such as JustGiving), and grants such as the National Lottery Community Fund award received in 2025 to support Community Day events. The organization has 1-10 employees and operates without commercial pricing, relying on community engagement, social media (Facebook, Twitter/X, Instagram, YouTube with 1.1K+ subscribers), newsletters, and earned media to reach patients and supporters. In 2025 it received a Highly Commended recognition from the Market Research Society in the MRS/ICG Independent Consultants category for patient-story-led advocacy supporting NHS access to burosumab for adults.
XLH UK firmographics
Firmographics- Name
- XLH UK
- Legal name
- XLH UK
- Website
- https://xlhuk.org
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- XLH UK is a patient-led UK charity supporting individuals and families affected by X-linked hypophosphataemia and related phosphate-wasting disorders through education, peer support, research participation, and NHS access advocacy.
- Ownership category
- akta.pro rank
Where XLH UK is headquartered
LocationHeadquarters
- HQ city
- Kington
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
XLH UK business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Distribution channels1 record
Marketing channels6 records
XLH UK product offering
Product offeringCore offering
XLH UK is a patient-led registered charity that supports individuals and families affected by X-linked hypophosphataemia (XLH) and related phosphate-wasting disorders in the United Kingdom. It delivers disease information, treatment guidance (including burosumab), peer-to-peer support through XLH Connect, a specialist finder, community events, and facilitates participation in the University of Oxford RUDY Study. Funding comes from donations, individual fundraising, and grants such as the National Lottery Community Fund.
Product overview
XLH UK operates as a patient advocacy and support charity offering a unified platform of services rather than a traditional product. The core offering includes patient support resources covering disease information, treatment guidance, and peer support through XLH Connect. The organization also facilitates participation in the RUDY Study for research purposes and provides an XLH Library of downloadable clinical resources and research publications. The charity focuses on community support, raising awareness, and improving care for those affected by X-linked hypophosphataemia and related disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- XLH UK Patient Support and Information Resources Comprehensive support platform providing information, resources, and community support for individuals and families affected by X-linked hypophosphataemia, including guidance on symptoms, dental health, physical and mental health, family planning, and treatment options.
- XLH Connect (Peer to Peer Support) Peer-to-peer support program connecting individuals and families affected by XLH to share experiences and provide mutual support.
- XLH UK Community Events (Community Day and Regional Family Days) In-person events bringing together the UK XLH community, including an annual Community Day conference in Birmingham, regional family days, and participation in Rare Disease Day activities.
- XLH Library Resource repository containing downloadable clinical practice recommendations, information leaflets, research publications, and consensus statements about XLH.
- RUDY Study (Patient-Reported Outcomes Research Partnership) A rare disease research study led by Oxford University that collects patient-reported data on XLH symptoms, treatment experiences, and quality of life to advance understanding and improve care.
- Find a Specialist Directory tool that helps XLH patients and families locate healthcare specialists experienced in diagnosing and treating X-linked hypophosphataemia in the UK.
Companies that use XLH UK
Customer profileSegments3 records
Ideal customer profiles3 records
XLH UK technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
XLH UK partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- University of Oxford (RUDY Study)coreThe RUDY Study is headed by a research team at the University of Oxford. It invites people with XLH and their caregivers to participate by completing questionnaires about symptoms, medicines, and daily life. The study collects data to strengthen the case for burosumab treatment and map UK availability, helping researchers understand XLH better.
- International XLH Alliance (IXLHA)coreXLH UK participates in the International XLH Alliance, which coordinates global XLH community efforts including awareness campaigns like Rare Disease Day selfie collages and sharing of best practices across countries.
- Agency For Goodminor
Recent moves6 records
Expansion highlights4 records
XLH UK competitors and assessment
Company assessmentRegional players
- Metabolic Support UK: UK charity supporting patients and families affected by inherited metabolic disorders, including rare bone and mineral conditions. Overlap with XLH UK on rare metabolic patient support, specialist finder resources, and community events.
- Brittle Bone Society: UK charity supporting people with osteogenesis imperfecta and other rare bone conditions. Comparable UK-based rare bone disease advocacy, peer support, and information resource model.
- Rare Diseases UK: UK-wide campaign coalition for people with rare diseases and all who support them. Comparable UK rare-disease advocacy, awareness events (Rare Disease Day), and policy engagement function.
- Genetic Alliance UK: UK umbrella organization for over 200 patient groups supporting people with genetic, rare, and undiagnosed conditions. Comparable peer-support and policy advocacy model focused on rare conditions in the UK.
Emerging players
- Soft Bones (Hypophosphatasia Foundation): Patient advocacy organization for hypophosphatasia, another rare phosphate-wasting metabolic bone disease. Comparable mission (rare metabolic bone disease patient support, awareness, research engagement) and similar scale.
- The Magic Foundation: US charity supporting families affected by a range of rare endocrine and growth conditions, including XLH and related disorders. Comparable niche patient-education and peer-support model for rare metabolic conditions.
Broad incumbents
- EURORDIS - Rare Diseases Europe: European-level alliance representing over 1,000 rare disease patient organizations. Comparable advocacy and community-building role but at significantly larger scale and broader disease scope than XLH UK.
- National Organization for Rare Disorders (NORD): US-based umbrella organization for rare disease patient groups with a comparable mission of patient support, research, and advocacy. Much larger scale but operates the same model of rare-disease community empowerment.
Direct peers
- International XLH Alliance (IXLHA): Global coalition of XLH patient organizations of which XLH UK is a member. Coordinates cross-country awareness, shares best practices, and represents the XLH community internationally.
- XLH Network: US-based patient advocacy organization dedicated to X-linked hypophosphataemia. Most directly comparable peer; serves the same disease community, runs peer support and educational resources, and engages on treatment access advocacy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
XLH UK social profiles
Digital presenceXLH UK financial estimates
Financial estimateRevenue estimate
Valuation estimate
XLH UK leadership team
Management profileNumber of profiles
XLH UK funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XLH UK M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XLH UK
What does XLH UK do?
XLH UK is a patient-led registered charity that supports individuals and families affected by X-linked hypophosphataemia (XLH) and related phosphate-wasting disorders in the United Kingdom. It delivers disease information, treatment guidance (including burosumab), peer-to-peer support through XLH Connect, a specialist finder, community events, and facilitates participation in the University of Oxford RUDY Study. Funding comes from donations, individual fundraising, and grants such as the National Lottery Community Fund.
Is XLH UK a public or private company?
XLH UK is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was XLH UK founded?
XLH UK was founded in 2021. It employs 1 to 10 people.
Where is XLH UK based?
XLH UK is headquartered in Kington, United Kingdom, in the Europe region.
Who are XLH UK's main competitors?
Regional players on record are Metabolic Support UK, Brittle Bone Society, Rare Diseases UK and Genetic Alliance UK. Emerging players are Soft Bones (Hypophosphatasia Foundation) and The Magic Foundation. Broad incumbents are EURORDIS - Rare Diseases Europe and National Organization for Rare Disorders (NORD). Direct peers are International XLH Alliance (IXLHA) and XLH Network.
Does XLH UK have an API?
No public API is recorded for XLH UK.